Results of all pathologists for phase I (n=41)
| Pathologist | Percentage of cases ‘indefinite for dysplasia’ | Percentage agreement (three categories)* | Consensus LGD and HGD cases underdiagnosed as NDBO (n (%)) n=28 |
| Core pathologists | |||
| 1 | 24.4 | 82.9 | 0 |
| 2 | 9.8 | 80.5 | 2 (7.1) |
| 3 | 22.0 | 80.5 | 1 (3.6) |
| 4 | 7.3 | 87.8 | 1 (3.6) |
| 5 | 9.8 | 78.0 | 3 (10.7) |
| New core pathologists | |||
| B | 12.2 | 78.0 | 1 (3.6) |
| E | 12.2 | 75.6 | 1 (3.6) |
| J | 17.1 | 73.2 | 1 (3.6) |
| Aspirant panel members | |||
| A | 12.2 | 39.0 | 16 (57.0) |
| C | 14.6 | 58.5 | 1 (3.6) |
| D | 31.7 | 65.9 | 2 (7.1) |
| F | 12.2 | 70.7 | 0 |
| G | 12.2 | 68.3 | 2 (7.1) |
| H | 7.3 | 68.3 | 1 (3.6) |
| I | 9.8 | 68.3 | 1 (3.6) |
| Benchmark value† | ≤28 | ≥69 | ≤3 (11) |
red, score does not fall within benchmark values
green, score falls within benchmark values
*NDBO/IND/LGD+HGD.
†Based on eight core pathologists.
HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; NDBO, non-dysplastic Barrett’s oesophagus.